Tonya Campbell
Datos Biográficos
| ID | 5410697 |
|---|---|
| NOMBRE | Tonya Campbell |
| NOMBRES | Tonya |
| APELLIDO | Campbell |
| FIRMA | CAMPBELL T |
| AFILIACIONES | St. Michael's Hospital |
| ORCID | 0000-0001-8459-208X |
| VERIFICADO | Sí |
| TOTAL DE OBRAS | 6 |
| TOTAL DE CITAS | 0 |
| TOTAL COMO AUTOR | 6 |
| TOTAL COMO EDITOR | 0 |
| PRIMER AÑO DE PUBLICACIÓN | 2022 |
| AÑO MÁS RECIENTE DE PUBLICACIÓN | 2025 |
| ÍNDICE H | 0 |
Changing trends in safer opioid supply uptake, dose and hydromorphone volume in Ontario
An accelerating number of safer opioid supply recipients over time, coupled with rising immediate-release hydromorphone doses likely reflects efforts to meet the needs of people who use drugs in the context of an increasingly potent unregulated opioid supply, particularly as this supply changed throughout the COVID-19 pandemic
Trends in the dispensing of opioids for pain and concurrent benzodiazepine use among First Nations People in Ontario, Canada, from 2013 to 2021
Opioid analgesic prescribing patterns for First Nations People living in Ontario indicate a decrease in both overall prescribing rates and concurrent benzodiazepine use
Assessing the impact of the slow-release oral morphine drug shortages in Ontario, Canada
The epidemiology of benzodiazepine-related toxicity in Ontario, Canada
Benzodiazepine-related toxicity has declined in Ontario overall, but has increased among youth and young adults. Furthermore, there is growing co-involvement of opioids, stimulants, and alcohol, which may reflect the recent emergence of benzodiazepines in the unregulated drug supply. Multifaceted public health initiatives comprising harm reduction, mental health supports, and promotion of appropriate prescribing are needed to reduce benzodiazepin…
Impact of the Covid-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada
Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada
Sin obras prominentes en esta página.
Impact of the Covid-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada
Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada
Assessing the impact of the slow-release oral morphine drug shortages in Ontario, Canada
The epidemiology of benzodiazepine-related toxicity in Ontario, Canada
Benzodiazepine-related toxicity has declined in Ontario overall, but has increased among youth and young adults. Furthermore, there is growing co-involvement of opioids, stimulants, and alcohol, which may reflect the recent emergence of benzodiazepines in the unregulated drug supply. Multifaceted public health initiatives comprising harm reduction, mental health supports, and promotion of appropriate prescribing are needed to reduce benzodiazepin…
Changing trends in safer opioid supply uptake, dose and hydromorphone volume in Ontario
An accelerating number of safer opioid supply recipients over time, coupled with rising immediate-release hydromorphone doses likely reflects efforts to meet the needs of people who use drugs in the context of an increasingly potent unregulated opioid supply, particularly as this supply changed throughout the COVID-19 pandemic
Trends in the dispensing of opioids for pain and concurrent benzodiazepine use among First Nations People in Ontario, Canada, from 2013 to 2021
Opioid analgesic prescribing patterns for First Nations People living in Ontario indicate a decrease in both overall prescribing rates and concurrent benzodiazepine use
Medicine (6 obras) · Opioid Use Disorder Treatment (6 obras) · Environmental health (5 obras) · Internal Medicine (5 obras) · Population (5 obras) · Opioid (4 obras) · Poisoning and overdose treatments (3 obras) · Anesthesia (2 obras) · Benzodiazepine (2 obras) · Emergency Medicine (2 obras)